London’s Sava raises €32.08 million and partners with Ascensia to bring its glucose microsensor to Europe
Sava Technologies, a London-based HealthTech company developing a wearable biosensor platform that detects molecules just beneath the skin, today announced a $36 million Series B round to fund manufacturing scale-up and commercial readiness. The round was led by Ascensia, with participation from institutional investors Balderton Capital, Norrsken VC, Simplyhealth Ventures, JamJar Investments,…
London-based HealthTech firm Sava Technologies has secured €32.08 million in a Series B funding round, led by Ascensia. This brings the company's total funding to $68 million. The investment will support manufacturing scale-up and commercial readiness for Sava's glucose microsensor. The partnership aims to bring this innovative technology to Europe, marking a significant advancement in diabetes care.
Written by urgent.news from EU-Startups's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
